Zacks Investment Research Downgrades TransMedics Group (NASDAQ:TMDX) to Sell

Zacks Investment Research lowered shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts. “

NASDAQ TMDX opened at $18.47 on Tuesday. TransMedics Group has a one year low of $16.92 and a one year high of $31.54. The stock has a 50-day simple moving average of $22.66. The company has a quick ratio of 6.82, a current ratio of 7.55 and a debt-to-equity ratio of 0.48.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.29). The company had revenue of $5.67 million during the quarter, compared to the consensus estimate of $5.59 million. On average, sell-side analysts expect that TransMedics Group will post -2.25 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Abrams Capital Management L.P. bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $87,820,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $5,697,000. AXA bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $5,769,000. Janus Henderson Group PLC bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $15,059,000. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of TransMedics Group during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 65.69% of the company’s stock.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Further Reading: What is the price-sales ratio?

Get a free copy of the Zacks research report on TransMedics Group (TMDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit